Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca and Isis broaden antisense deal

This article was originally published in Scrip

Executive Summary

AstraZeneca and Isis Pharmaceuticals have expanded their alliance in the field of antisense therapies, with the UK major paying $65m up front to Isis as part of the agreement. They will collaborate to discover and develop new treatments for cardiovascular, metabolic and renal diseases, in a move that extends Isis's R&D into kidney disease, a new area for the company. The deal will also include development and regulatory milestones for each program that advances, as well as double-digit tiered royalties on net sales of any resulting products that are ultimately commercialized. The two companies first partnered to develop antisense therapies against cancer targets in 2012, in a collaboration that was worth $31m up front to Isis but which the company boasted could be ultimately worth in excess of $1bn. The following year that deal was expanded to include metabolic and cardiovascular indications. They later expanded their partnership to discover and develop novel delivery methods for antisense oligonucleotides in November 2014. The lead compound in the cancer collaboration, AZD9150/ISIS-STAT3-2.5Rx, targeting STAT3, has reached Phase II.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029405

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel